Following the first public consultation on Sept. 28, 2020, and the second public consultation on Sept. 29, 2021, China National Medical Products Administration (NMPA) released the finalized Measures for the Management of Cosmetic Adverse Reaction Monitoring (the Measures) on Feb. 21, 2022, which will take effect on Oct. 1, 2022. 1